Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Comparison of PIK3CA mutation studies in male and female breast cancer

From: PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer

  Male Breast Cancer Female Breast Cancer
  Current Study Benvenuti S et al. [20] Benvenuti S et al. [20] Buttitta F et al. [14] Campbell IG et al. [3] Saal H et al. [16]
Study population High risk - familial Population based Population based Population based Population based Population based
Frequency 6/57 (10.5%) 7/39 (17.9%) 14/86 (16.3%) 46/180 (25.6%) 28/70 (40.0%) 77/292 (26.4%)
Mutation Locus 3 exon 9, 3 exon 20 7 exon 20 6 exon 9, 8 exon 20 23 exon 9, 23 exon 20 15 exon 9, 9 exon 20, 3 exon 7, 1 exon 6 31 exon 9, 49 exon 20, 7 exon 7, 7 others
Clinicopathological association Inverse correlation with BRCA2 mutation carrier status No clinicopathological association No clinicopathological association Mutation seen more frequently in lobular carcinoma (46%, P < 0.001). Exon 9 more frequently seen in lobular carcinoma (30% of cases, P < 0.001). No clinicopathological association Association with ER positivity (P = 0.0001), PgR Positivity (0.0063) and lymph node positivity (P = 0.0375).
  1. P-values < 0.05 in bold text